...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib
【24h】

Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib

机译：索拉非尼治疗肝细胞癌患者的不良事件与微生物的关系

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Sorafenib results in several adverse events, the mechanism and predictors of which are unknown. Recently, it was reported that metabolism by microbiome changes the structure and effects of drugs. The blood levels of sorafenib may be affected by enterohepatic recycling of sorafenib due to microbial enzymes in the gut. We evaluated the relationship between adverse events caused by sorafenib treatment and microbiome in patients with advanced hepatocellular carcinoma. Materials and Methods: Twenty-five patients were classified into two groups based on the presence of hand-foot syndrome (HFS) or diarrhea within 12 weeks post-sorafenib treatment. Before sorafenib treatment, the fecal samples were analyzed targeting the V3-V4 region of 16s ribosomal RNA. Microbiome and predicted functional gene were compared between two groups. Results: The non-HFS group had a richer abundance of Veillonella, Bacillus, Enterobacter, Faecalibacterium, Lachnospira, Dialister, and Anaerostipes than the HFS group at genus level. Carotenoid biosynthesis and bacterial invasion of epithelial cells were enriched in the HFS group. The former three bacteria are classified as oral-origin bacteria, and the two predicted functions are associated with dysbiosis. The non-diarrhea group had a higher abundance of Butyricimonas and a lower abundance of Citrobacter, Peptostreptococcus, and Staphylococcaceae than the diarrhea group. Eight categories of predicted functional genes were detected with differences between the two groups. Conclusion: The non-HFS group had a higher relative abundance of oral-origin bacteria, which likely led to more robust dysbiosis in the gut. This dysbiosis may affect enterohepatic recycling. Additionally, the metabolism of these short-chain fatty acids in the gut may be different between the diarrhea and non-diarrhea groups.
机译：背景/目的：索拉非尼导致若干不利事件，其机制和预测因子是未知的。最近，据报道，微生物组的新陈代谢改变了药物的结构和影响。由于肠道中的微生物酶，Sorafenib的血液水平可能受索拉非尼酸的肠呼吸缺口再循环的影响。我们评估了脱脂癌患者Sorafenib治疗和微生物组造成的不良事件之间的关系。材料和方法：将二十五名患者分为两组，基于索拉尼治疗后12周内的手足综合征（HFS）或腹泻的存在。在Sorafenib处理之前，分析粪便样品靶向16S核糖体RNA的V3-V4区域。在两组之间比较微生物组和预测的官能基因。结果：非HFS组富裕丰富的veillonella，芽孢杆菌，肠杆菌，粪便，Lachnospira，拨号和厌氧体，而不是属的HFS组。类胡萝卜素生物合成和上皮细胞的细菌侵袭在HFS组中富集。前三种细菌被归类为口服源性细菌，并且两个预测的功能与脱敏相关。非腹泻组具有较高丰富的丁霉素和较低丰富的酸杆菌，Peptostropococcus和葡萄球菌比腹泻组。在两组之间的差异检测八类预测的功能基因。结论：非HFS组具有更高的口腔原产地细菌，这可能导致肠道中更加强有力的困难。这种缺陷症可能会影响肠溶回收率。另外，肠道中这些短链脂肪酸的代谢可能不同于腹泻和非腹泻基团之间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号